Important safety considerations: Seek urgent same-day medical assessment via NHS 111 or A&E for severe abdominal pain (potential pancreatitis) and stop taking the medication pending review Report persistent nausea, vomiting, or signs of dehydration Be aware of increased hypoglycaemia risk if taking insulin or sulfonylureas (dose adjustments may be needed) Attend regular monitoring appointments for kidney function, diabetic retinopathy, and other parameters Discuss contraception if you are of childbearing potential, as GLP-1 receptor agonists are generally not recommended during pregnancy or breastfeeding [11] Report any suspected side effects via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk) Specific administration requirements vary by product
After quality filtering (Supplementary Fig
Strategy for prevention Preventing misuse among those with eating disorders requires a coordinated strategy across clinical, regulatory and professional domains
Gastrointestinal adverse reactions, including diarrhea, were the most common reason for treatment discontinuation in clinical trials, with approximately 4-7% of patients discontinuing due to GI events
Kolesnikova LI, Kurashova NA, Bairova TA et al (2017) Role of glutathione-S-transferase family genes in male infertility
